Dimerix secures A$17 million drawdown, fully funded through ACTION3 Phase 3 trial
Dimerix Limited (ASX: DXB) has completed the initial drawdown of A$17 million under its previously announced A$34 million non-dilutive funding facility, with the receipt confirmed on 23 September 2026. The drawdown represents 50% of the committed facility amount, and the company confirms its funding position is considered sufficient to complete the ACTION3 Phase 3 trial of DMX-200 and continue Phase 2 advancement of DMX-652 in Acute Kidney Injury.
For a clinical-stage biotech, confirming funded status through a pivotal Phase 3 readout removes one of the most significant risks for investors: funding uncertainty. The remaining A$17 million remains available at Dimerix’s election until 31 March 2027, subject to facility terms. The facility also provides an option to increase total commitments to up to A$50 million prior to 31 March 2027, though the company currently has no plans to access this additional funding.
Dr Nina Webster, CEO and Managing Director, Dimerix
“The receipt of these funds further strengthens Dimerix’s financial position and supports the continued execution of our key value-driving programs, including the ACTION3 Phase 3 study of DMX-200 and the advancement of DMX-652. Importantly, we have maintained our disciplined approach to capital management by drawing only 50% of the facility at this time. This minimises financing costs while providing significant flexibility to access the remaining committed funds should they be required in the future. The facility is an attractive non-dilutive source of capital that allows us to advance our development and commercialisation activities while preserving value for existing shareholders…”
When big ASX news breaks, our subscribers know first
What non-dilutive funding means for DXB shareholders
A non-dilutive funding facility provides capital without issuing new shares, meaning existing shareholders are not diluted by the raise. This contrasts with equity-based instruments such as placements or share purchase plans, where new shares are created and the value of existing holdings can be reduced.
Dimerix has drawn only 50% of the facility at this stage, consistent with its stated strategy of accessing only the level of capital required for planned operations. Key advantages of this structure include:
- No new shares issued, meaning existing shareholders retain their proportionate stake
- Drawdown timing is at Dimerix’s election, giving the company control over when and whether to access the remaining funds
- Repayment is anticipated through existing licensee milestone payments, potential new licence fees, and/or capital market access, rather than asset sales
Management has explicitly framed shareholder value preservation as a priority underpinning this approach.
Pipeline progress: ACTION3 and DMX-652 advancing toward key catalysts
DMX-200 in FSGS — fully recruited Phase 3 trial underway
The ACTION3 Phase 3 trial is evaluating DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a serious and rare kidney disease characterised by progressive scarring in the kidney’s filtering units that can lead to kidney failure, dialysis, or the need for transplantation.
More than 40,000 people in the United States are estimated to be living with FSGS, and there are currently no therapies specifically approved for the condition in the US. In patients with progressive or treatment-resistant FSGS, the average time from diagnosis to end-stage kidney disease can be as short as five years. The trial is fully recruited and advancing, though the announcement does not disclose a specific data readout date.
The ACTION3 trial reached full recruitment with 333 patients enrolled across 21 countries, exceeding its original 286-patient target, a deliberate over-recruitment that strengthens statistical power for the primary proteinuria endpoint ahead of the March 2028 readout.
DMX-200 holds Orphan Drug Designation in the United States, Europe, the UK, and Japan. Patents are granted in various territories until 2032, with applications submitted globally that may extend protection to 2042.
DMX-652 in Acute Kidney Injury — Phase 2 underway
DMX-652 is a selective inhibitor of USP30, a mitochondrial enzyme, delivered as a once-daily oral capsule. The Phase 2 program is designed to evaluate DMX-652’s potential to prevent kidney injury and preserve renal function following cardiac surgery.
The US Food and Drug Administration (FDA) has approved the Phase 2 protocol to proceed. The current addressable patient population is estimated at approximately 260,000 annually across major markets including the United States, Germany, France, Italy, Spain, and the United Kingdom, making this indication a potential orphan designation.
The DMX-652 acquisition structure was designed to keep near-term capital exposure low, with a US$5 million upfront payment against up to US$287 million in potential milestones, and the asset arrived Phase 2-ready with an open US IND, an FDA-approved protocol, and sufficient GMP drug supply already in place.
Pipeline snapshot:
- DMX-200: Phase 3 (ACTION3, fully recruited) | FSGS | Orphan Drug Designation (US, EU, UK, Japan)
- DMX-652: Phase 2 (FDA-approved protocol) | Acute Kidney Injury | Potential orphan designation
Commercial foundation and what comes next
The funding drawdown sits within a broader commercial framework that Dimerix has established across major markets. Based on aggregate figures from the company’s 6 August 2026 ASX Investor Presentation, Dimerix has secured five commercial partners, receiving A$81 million in upfront payments to date, with a further A$237 million in potential development milestone payments available ahead of commercial launch.
| Program | Stage | Commercial Partners | Upfront Received | Development Milestones Available |
|---|---|---|---|---|
| DMX-200 (FSGS) | Phase 3 (fully recruited) | 5 partners across major markets | A$81 million | A$237 million |
The remaining A$17 million available under the facility until 31 March 2027 provides strategic optionality as Dimerix progresses both programs. Repayment is anticipated through the existing licensee milestone structure and potential new licence fees, preserving the non-dilutive character of the arrangement. The company also confirms it continues to pursue licensing opportunities in territories not already licensed for DMX-200.
Taken together, the combination of non-dilutive funding confirming runway through a pivotal Phase 3 trial, a second Phase 2 program advancing with FDA-approved protocol, A$237 million in potential development milestones ahead of commercial launch, and five established commercial partners positions Dimerix with multiple near- and medium-term catalysts across its kidney disease pipeline.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to start receiving alerts today.